TNFRSF13C (Q96RJ3) variants and mutations
TNFRSF13C (also known as Q96RJ3) is a human protein-coding gene encoding a tumor necrosis factor receptor superfamily member 13C protein. It provides a crucial survival signal for transitional and mature B cells in response to BAFF. Biallelic loss-of-function variants can cause antibody deficiency with markedly reduced mature B-cell numbers. This analysis covers 533 TNFRSF13C variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes immunodeficiency, common variable, 4, common variable immunodeficiency, and recurrent infections associated with rare immunoglobulin isotypes deficiency. Example TNFRSF13C variants include M1K, R2K, and R3L.
Variant analysis overview
- Gene: TNFRSF13C
- Protein: Q96RJ3
- UniProt accession: Q96RJ3
- Organism: Homo sapiens
- Variants analyzed: 533
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 234 unspecified-consequence records; 1 stop lost; 166 missense variants; 100 synonymous variants; 7 stop-gained variants; 13 frameshift variants; 3 in-frame insertions; 7 in-frame deletions; 2 splice-region variants; 1 substitution
- Prediction scores: 496 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: immunodeficiency, common variable, 4, common variable immunodeficiency, recurrent infections associated with rare immunoglobulin isotypes deficiency, systemic lupus erythematosus, Sjogren syndrome, autoimmune thrombocytopenic purpura, lupus nephritis, autoimmune hemolytic anemia, autoimmune hepatitis, immunodeficiency, common variable, 2, B-cell chronic lymphocytic leukemia, rheumatoid arthritis.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments.
- Structural context: 70 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable TNFRSF13C variants
Examples include M1K, R2K, R3L, R3Q, G4A, G4E, P5H, P5L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1K (p.Met1Lys), rs1299112321, ClinGen CA411763988, ClinVar RCV002024398, MetaLR 0.06, MetaSVM -1.07, Uncertain significance, Immunodeficiency, common variable, 4
- R2K (p.Arg2Lys), rs2077635510, ClinGen CA411763973, ClinVar RCV003611928, TOPMed rs2077635510, REVEL 0.01, CADD 0.18, Uncertain significance, Immunodeficiency, common variable, 4
- R3L (p.Arg3Leu), TOPMed rs2077635492, gnomAD rs2077635492, REVEL 0.01, CADD 8.14
- R3Q (p.Arg3Gln), NCI-TCGA TCGA novel, REVEL 0.01, CADD 7.08, Variant assessed as somatic; moderate impact.
- G4A (p.Gly4Ala), rs2077635455, ClinGen CA411763947, ClinVar RCV002847429, ClinVar RCV004695257, REVEL 0.07, CADD 15.30, Uncertain significance, not provided; Immunodeficiency, common variable, 4
- G4E (p.Gly4Glu), rs2077635455, ClinGen CA411763948, ClinVar RCV001369488, TOPMed rs2077635455, REVEL 0.04, CADD 16.30, Uncertain significance, Immunodeficiency, common variable, 4
- P5H (p.Pro5His), rs921374310, ClinGen CA411763939, ClinVar RCV001896129, TOPMed rs921374310, REVEL 0.04, CADD 12.60, Uncertain significance, Immunodeficiency, common variable, 4
- P5L (p.Pro5Leu), TOPMed rs921374310, gnomAD rs921374310, REVEL 0.01, CADD 7.90, Uncertain significance, Immunodeficiency, common variable, 4
- P5S (p.Pro5Ser), gnomAD rs1172812848, REVEL 0.01, CADD 0.10, Uncertain significance, Immunodeficiency, common variable, 4
- R6L (p.Arg6Leu), NCI-TCGA TCGA novel, REVEL 0.14, CADD 22.60, Variant assessed as somatic; moderate impact.
- R6P (p.Arg6Pro), 1000Genomes rs1282859624, TOPMed rs1282859624, REVEL 0.14, CADD 19.50, Uncertain significance
- R6Q (p.Arg6Gln), rs1282859624, ClinGen CA411763934, ClinVar RCV004217723, 1000Genomes rs1282859624, REVEL 0.09, CADD 22.60, Uncertain significance, not specified
- L8Q (p.Leu8Gln), gnomAD rs2077635266, REVEL 0.02, CADD 0.17
- R9L (p.Arg9Leu), TOPMed rs2077635183, gnomAD rs2077635183, REVEL 0.03, CADD 17.60
- R9Q (p.Arg9Gln), TOPMed rs2077635183, gnomAD rs2077635183, REVEL 0.05, CADD 14.20
- R9W (p.Arg9Trp), rs1161872026, ClinGen CA411763902, ClinVar RCV003611832, gnomAD rs1161872026, REVEL 0.09, AlphaMissense 0.07, Uncertain significance, Immunodeficiency, common variable, 4
- G10D (p.Gly10Asp), rs2518792157, ClinGen CA411763888, ClinVar RCV003860845, REVEL 0.11, CADD 22.10, Uncertain significance, Immunodeficiency, common variable, 4
- D12G (p.Asp12Gly), rs1215819338, ClinGen CA411763862, ClinVar RCV001954667, TOPMed rs1215819338, REVEL 0.04, CADD 18.60, Uncertain significance, Immunodeficiency, common variable, 4
- A13S (p.Ala13Ser), rs2077635069, ClinGen CA411763854, ClinVar RCV001222123, Ensembl rs2077635069, REVEL 0.01, CADD 7.41, Uncertain significance, Immunodeficiency, common variable, 4
- A13V (p.Ala13Val), gnomAD rs1181763159, REVEL 0.04, CADD 14.90
- P14T (p.Pro14Thr), gnomAD rs1257068594, REVEL 0.04, AlphaMissense 0.13
- A15V (p.Ala15Val), Ensembl rs2077634958, REVEL 0.01, CADD 1.05
- P16A (p.Pro16Ala), rs2518792116, ClinGen CA411763823, ClinVar RCV003611130, REVEL 0.08, CADD 19.60, Uncertain significance, Immunodeficiency, common variable, 4
- P16L (p.Pro16Leu), ExAC rs774206132, gnomAD rs774206132, REVEL 0.14, CADD 24.10
- T17K (p.Thr17Lys), gnomAD rs2077634892, REVEL 0.08, CADD 23.70
- T17R (p.Thr17Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- P18S (p.Pro18Ser), rs2077634829, ClinGen CA411763803, ClinVar RCV003838181, TOPMed rs2077634829, REVEL 0.01, CADD 10.70, Uncertain significance, Immunodeficiency, common variable, 4
- C19F (p.Cys19Phe), gnomAD rs1242212632, REVEL 0.43, CADD 23.40
- V20I (p.Val20Ile), NCI-TCGA TCGA novel, REVEL 0.02, CADD 0.08, Variant assessed as somatic; moderate impact.
- P21Q (p.Pro21Gln), 1000Genomes rs77874543, ESP rs77874543, ExAC rs77874543, TOPMed rs77874543, REVEL 0.02, CADD 2.06, Benign
- P21R (p.Pro21Arg), rs77874543, ClinGen CA10262524, ClinVar RCV000648324, ClinVar RCV001643043, REVEL 0.03, CADD 8.23, Conflicting interpretations, not specified; Immunodeficiency, common variable, 4; not provided
- E23* (p.Glu23Ter), TOPMed rs2077634682, CADD 25.30
- E23G (p.Glu23Gly), rs2518792060, ClinGen CA411763735, ClinVar RCV003613436, REVEL 0.04, CADD 19.70, Uncertain significance, Immunodeficiency, common variable, 4
- V29I (p.Val29Ile), rs2518792027, ClinGen CA411763657, ClinVar RCV003503098, REVEL 0.06, CADD 9.24, Uncertain significance, Immunodeficiency, common variable, 4
- R30H (p.Arg30His), rs1334352355, ClinGen CA411763637, ClinVar RCV001318142, TOPMed rs1334352355, REVEL 0.17, CADD 24.30, Uncertain significance, Immunodeficiency, common variable, 4
- V33A (p.Val33Ala), TOPMed rs2077634573, gnomAD rs2077634573, REVEL 0.27, CADD 24.30, Uncertain significance, Immunodeficiency, common variable, 4
- V33M (p.Val33Met), TOPMed rs1302959129, REVEL 0.27, CADD 23.60
- A34D (p.Ala34Asp), rs777204893, ClinGen CA10262523, ClinVar RCV002017173, ExAC rs777204893, REVEL 0.07, CADD 6.31, Uncertain significance, Immunodeficiency, common variable, 4
- A34V (p.Ala34Val), rs777204893, ClinGen CA411763589, ClinVar RCV003063776, REVEL 0.13, CADD 18.50, Uncertain significance, Immunodeficiency, common variable, 4
- C35G (p.Cys35Gly), TOPMed rs1438898938
- G36E (p.Gly36Glu), TOPMed rs2077634478, REVEL 0.04, CADD 0.03, Uncertain significance, Immunodeficiency, common variable, 4
- L38Q (p.Leu38Gln), gnomAD rs2077634412, REVEL 0.14, CADD 24.20
- R39H (p.Arg39His), Ensembl rs950637392, REVEL 0.07, CADD 16.40
- P41L (p.Pro41Leu), rs1556159000, ClinGen CA411763512, ClinVar RCV000576165, Ensembl rs1556159000, REVEL 0.09, CADD 22.40, Uncertain significance, Immunodeficiency, common variable, 4
- R42Q (p.Arg42Gln), rs2518791960, ClinGen CA411763504, ClinVar RCV004303598, NCI-TCGA TCGA novel, REVEL 0.01, CADD 13.30, Uncertain significance, not specified
- R42W (p.Arg42Trp), gnomAD rs2077634292, REVEL 0.06, CADD 22.90
- P43L (p.Pro43Leu), rs2077634246, ClinGen CA411763490, ClinVar RCV002020238, TOPMed rs2077634246, REVEL 0.17, CADD 23.50, Uncertain significance, Immunodeficiency, common variable, 4
- P43R (p.Pro43Arg), TOPMed rs2077634246, gnomAD rs2077634246, REVEL 0.18, CADD 23.50, Uncertain significance
- P43S (p.Pro43Ser), TOPMed rs1369166722, gnomAD rs1369166722, REVEL 0.01, CADD 16.10
- K44E (p.Lys44Glu), Ensembl rs2077634200
- P45L (p.Pro45Leu), rs1028425566, ClinGen CA411763465, ClinVar RCV001897180, TOPMed rs1028425566, REVEL 0.02, CADD 14.10, Uncertain significance, Immunodeficiency, common variable, 4
- P45Q (p.Pro45Gln), TOPMed rs1028425566, gnomAD rs1028425566, REVEL 0.04, CADD 17.40, Uncertain significance
- P45R (p.Pro45Arg), rs1028425566, ClinGen CA411763468, ClinVar RCV003504109, TOPMed rs1028425566, REVEL 0.01, CADD 14.00, Uncertain significance, Immunodeficiency, common variable, 4
- A46G (p.Ala46Gly), 1000Genomes rs750766446, ExAC rs750766446, gnomAD rs750766446, REVEL 0.04, CADD 12.00, Uncertain significance, Immunodeficiency, common variable, 4; not specified
- A46V (p.Ala46Val), 1000Genomes rs750766446, ExAC rs750766446, gnomAD rs750766446, REVEL 0.07, CADD 22.10, Uncertain significance
- A46A (p.Ala46Ala), gnomAD 22-41926330-G-T, CADD 1.71
- A46D (p.Ala46Asp), gnomAD 22-41926331-G-T, REVEL 0.06, MetaLR 0.12
- G47R (p.Gly47Arg), rs1301803591, gnomAD rs1301803591, REVEL 0.04, CADD 4.56, Uncertain significance, Immunodeficiency, common variable, 4
- G47G (p.Gly47Gly), rs2077630830, gnomAD 22-41926327-C-A, CADD 2.44
- G47E (p.Gly47Glu), gnomAD 22-41926328-C-T, REVEL 0.04, MetaLR 0.04
- G47V (p.Gly47Val), gnomAD 22-41926328-C-A, REVEL 0.06, MetaLR 0.04
- G47W (p.Gly47Trp), gnomAD 22-41926329-C-A, REVEL 0.09, MetaLR 0.08
- A48P (p.Ala48Pro), TOPMed rs1407623179, gnomAD rs1407623179, REVEL 0.01, CADD 6.98, Uncertain significance
- A48S (p.Ala48Ser), TOPMed rs1407623179, gnomAD rs1407623179, REVEL 0.03, CADD 2.57, Uncertain significance
- A48T (p.Ala48Thr), rs1407623179, ClinGen CA411763413, ClinVar RCV001950658, TOPMed rs1407623179, REVEL 0.02, CADD 6.75, Uncertain significance, Immunodeficiency, common variable, 4
- A48A (p.Ala48Ala), rs1332317183, gnomAD 22-41926324-G-A, CADD 3.29
- A48V (p.Ala48Val), gnomAD 22-41926325-G-A, REVEL 0.03, MetaLR 0.04
- A48D (p.Ala48Asp), gnomAD 22-41926325-G-T, REVEL 0.04, MetaLR 0.03
- S49G (p.Ser49Gly), 1000Genomes rs2146589499, REVEL 0.09, CADD 21.90
- S49N (p.Ser49Asn), gnomAD rs1167478636, REVEL 0.06, CADD 21.80
- S49R (p.Ser49Arg), gnomAD 22-41926320-TG-T, CADD 25.30
- S49S (p.Ser49Ser), rs1474469071, gnomAD 22-41926321-G-A, CADD 9.90
- S49I (p.Ser49Ile), gnomAD 22-41926322-C-A, REVEL 0.07, MetaLR 0.09
- S49T (p.Ser49Thr), gnomAD 22-41926322-C-G, REVEL 0.08, MetaLR 0.04
- S49A (p.Ser49Ala), gnomAD 22-41926323-TG-T, CADD 11.30
- S50N (p.Ser50Asn), rs997496855, ClinGen CA324633637, ClinVar RCV003852224, TOPMed rs997496855, REVEL 0.03, CADD 21.40, Uncertain significance, Immunodeficiency, common variable, 4
- S50R (p.Ser50Arg), gnomAD 22-41926318-G-T, REVEL 0.04, MetaLR 0.09
- S50S (p.Ser50Ser), gnomAD 22-41926318-G-A, CADD 8.45
- S50I (p.Ser50Ile), gnomAD 22-41926319-C-A, REVEL 0.06, MetaLR 0.10
- S50T (p.Ser50Thr), gnomAD 22-41926319-C-G, REVEL 0.06, MetaLR 0.06
- S50G (p.Ser50Gly), gnomAD 22-41926320-T-C, REVEL 0.07, MetaLR 0.05
- P51L (p.Pro51Leu), TOPMed rs1355074916, gnomAD rs1355074916, REVEL 0.03, CADD 2.38, Uncertain significance, Immunodeficiency, common variable, 4
- P51S (p.Pro51Ser), gnomAD rs1374943212, REVEL 0.04, CADD 2.57
- P51P (p.Pro51Pro), gnomAD 22-41926315-A-T, CADD 7.88
- P51H (p.Pro51His), gnomAD 22-41926316-G-T, REVEL 0.06, MetaLR 0.04
- P51A (p.Pro51Ala), gnomAD 22-41926317-G-C, REVEL 0.07, MetaLR 0.03
- P51T (p.Pro51Thr), gnomAD 22-41926317-G-T, REVEL 0.03, MetaLR 0.04
- A52T (p.Ala52Thr), rs2146589489, ClinGen CA411763386, ClinVar RCV003132911, Ensembl rs2146589489, REVEL 0.14, CADD 16.80, Likely pathogenic, Immunodeficiency, common variable, 4
- A52A (p.Ala52Ala), gnomAD 22-41926312-C-A, CADD 2.50
- A52G (p.Ala52Gly), gnomAD 22-41926313-G-C, REVEL 0.04, MetaLR 0.05
- A52E (p.Ala52Glu), gnomAD 22-41926313-G-T, REVEL 0.05, MetaLR 0.04
- A52V (p.Ala52Val), gnomAD 22-41926313-G-A, REVEL 0.14, MetaLR 0.05
- A52S (p.Ala52Ser), gnomAD 22-41926314-C-A, REVEL 0.09, MetaLR 0.04
- A52P (p.Ala52Pro), gnomAD 22-41926314-C-G, REVEL 0.12, MetaLR 0.07
- P53H (p.Pro53His), Ensembl rs2146589479, REVEL 0.07, CADD 22.90
- P53S (p.Pro53Ser), ExAC rs779354629, gnomAD rs779354629, REVEL 0.03, CADD 15.10
- P53P (p.Pro53Pro), gnomAD 22-41926309-G-A, CADD 3.81
- P53L (p.Pro53Leu), gnomAD 22-41926310-G-A, REVEL 0.09, MetaLR 0.05
- R54G (p.Arg54Gly), gnomAD rs1478002913, REVEL 0.01, CADD 5.29
- R54T (p.Arg54Thr), TOPMed rs2077630555, REVEL 0.06, CADD 13.10
- R54R (p.Arg54Arg), rs1242718283, gnomAD 22-41926306-C-T, CADD 3.66
- R54K (p.Arg54Lys), gnomAD 22-41926307-C-T, REVEL 0.07, MetaLR 0.03
- R54M (p.Arg54Met), gnomAD 22-41926307-C-A, REVEL 0.08, MetaLR 0.04
- T55A (p.Thr55Ala), TOPMed rs2077630519, REVEL 0.04, CADD 15.10
- T55T (p.Thr55Thr), rs886057590, gnomAD 22-41926303-C-T, CADD 1.22
- T55M (p.Thr55Met), gnomAD 22-41926304-G-A, REVEL 0.09, MetaLR 0.10
- T55K (p.Thr55Lys), gnomAD 22-41926304-G-T, REVEL 0.08, MetaLR 0.06
- A56P (p.Ala56Pro), TOPMed rs1453310836, gnomAD rs1453310836, REVEL 0.15, CADD 22.80
- A56A (p.Ala56Ala), rs1290517007, gnomAD 22-41926300-C-T, CADD 6.48
- A56G (p.Ala56Gly), gnomAD 22-41926301-G-C, REVEL 0.06, MetaLR 0.07
- A56E (p.Ala56Glu), gnomAD 22-41926301-G-T, REVEL 0.12, MetaLR 0.09
- A56V (p.Ala56Val), gnomAD 22-41926301-G-A, REVEL 0.02, MetaLR 0.04
- A56S (p.Ala56Ser), gnomAD 22-41926302-C-A, REVEL 0.04, MetaLR 0.05
- A56T (p.Ala56Thr), gnomAD 22-41926302-C-T, REVEL 0.05, MetaLR 0.05
- L57Q (p.Leu57Gln), gnomAD rs1194683094, REVEL 0.17, CADD 23.40, Uncertain significance, Immunodeficiency, common variable, 4
- L57L (p.Leu57Leu), gnomAD 22-41926297-C-A, CADD 7.76
- L57P (p.Leu57Pro), gnomAD 22-41926298-A-G, REVEL 0.20, MetaLR 0.15
- Q58L (p.Gln58Leu), rs1602373983, ClinGen CA411763346, ClinVar RCV000802509, Ensembl rs1602373983, REVEL 0.06, CADD 19.10, Uncertain significance, Immunodeficiency, common variable, 4
- Q58P (p.Gln58Pro), Ensembl rs1602373983, Uncertain significance
- Q58H (p.Gln58His), gnomAD 22-41926294-C-A, REVEL 0.03, MetaLR 0.05
- Q58Q (p.Gln58Gln), rs1336911972, gnomAD 22-41926294-C-T, CADD 5.96
- Q58R (p.Gln58Arg), gnomAD 22-41926295-T-C, REVEL 0.05, MetaLR 0.05
- Q58* (p.Gln58Ter), gnomAD 22-41926296-G-A, CADD 37.00
- Q58K (p.Gln58Lys), gnomAD 22-41926296-G-T, REVEL 0.03, MetaLR 0.05
- Q58E (p.Gln58Glu), gnomAD 22-41926296-G-C, REVEL 0.04, MetaLR 0.04
- P59L (p.Pro59Leu), TOPMed rs899866976, gnomAD rs899866976, REVEL 0.13, CADD 20.30
- P59Q (p.Pro59Gln), TOPMed rs899866976, gnomAD rs899866976, REVEL 0.11, CADD 22.90
- P59P (p.Pro59Pro), gnomAD 22-41926291-C-T, CADD 1.44
- P59T (p.Pro59Thr), gnomAD 22-41926293-G-T, REVEL 0.12, MetaLR 0.11
- P59S (p.Pro59Ser), gnomAD 22-41926293-G-A, REVEL 0.16, MetaLR 0.12
- Q60R (p.Gln60Arg), gnomAD rs1218905041, REVEL 0.10, CADD 19.60
- Q60H (p.Gln60His), gnomAD 22-41926288-C-A, REVEL 0.10, MetaLR 0.11
- Q60Q (p.Gln60Gln), gnomAD 22-41926288-C-T, CADD 5.77
- Q60P (p.Gln60Pro), gnomAD 22-41926289-T-G, REVEL 0.17, MetaLR 0.11
- Q60* (p.Gln60Ter), gnomAD 22-41926290-G-A, CADD 36.00
- E61K (p.Glu61Lys), rs1052712048, ClinGen CA324633622, ClinVar RCV000576214, TOPMed rs1052712048, REVEL 0.04, CADD 17.20, Uncertain significance, Immunodeficiency, common variable, 4
- E61D (p.Glu61Asp), gnomAD 22-41926285-C-A, REVEL 0.06, MetaLR 0.06
- E61E (p.Glu61Glu), gnomAD 22-41926285-C-T, CADD 7.70
- E61G (p.Glu61Gly), gnomAD 22-41926286-T-C, REVEL 0.07, MetaLR 0.07
- E61* (p.Glu61Ter), gnomAD 22-41926287-C-A, CADD 36.00
- S62W (p.Ser62Trp), gnomAD rs1281840629, REVEL 0.16, CADD 25.40
- S62S (p.Ser62Ser), gnomAD 22-41926282-C-G, CADD 5.05
- S62L (p.Ser62Leu), gnomAD 22-41926283-G-A, REVEL 0.06, MetaLR 0.06
- S62A (p.Ser62Ala), gnomAD 22-41926284-A-C, REVEL 0.01, MetaLR 0.04
- S62V (p.Ser62Val), gnomAD 22-41926285-C-CT, CADD 23.40
- V63M (p.Val63Met), 1000Genomes rs2146589432
- V63V (p.Val63Val), rs1379574923, gnomAD 22-41926279-C-A, CADD 8.61
- V63L (p.Val63Leu), gnomAD 22-41926281-C-A, REVEL 0.07, MetaLR 0.04
- G64D (p.Gly64Asp), 1000Genomes rs547352394, ExAC rs547352394, TOPMed rs547352394, gnomAD rs547352394, REVEL 0.04, CADD 19.80, Benign
- G64S (p.Gly64Ser), rs1439217837, ClinGen CA411763311, ClinVar RCV001063510, gnomAD rs1439217837, REVEL 0.07, CADD 18.10, Uncertain significance, Immunodeficiency, common variable, 4
- G64V (p.Gly64Val), rs1556157858, ClinGen CA658658924, ClinVar RCV000538153, Ensembl rs1556157858, REVEL 0.03, CADD 18.90, Benign/Likely benign, not specified; Immunodeficiency, common variable, 4
- G64G (p.Gly64Gly), gnomAD 22-41926276-G-T, CADD 6.42
- A65E (p.Ala65Glu), TOPMed rs1366486873, gnomAD rs1366486873, REVEL 0.05, CADD 15.30
- A65A (p.Ala65Ala), gnomAD 22-41926273-C-A, CADD 2.29
- A65V (p.Ala65Val), gnomAD 22-41926274-G-A, REVEL 0.04, MetaLR 0.05
- A65T (p.Ala65Thr), gnomAD 22-41926275-C-T, REVEL 0.01, MetaLR 0.05
- A65S (p.Ala65Ser), gnomAD 22-41926275-C-A, REVEL 0.01, MetaLR 0.05
- G66R (p.Gly66Arg), gnomAD rs1402585409, REVEL 0.08, CADD 22.80
- p.Gly66 Ala71del, gnomAD 22-41926254-GCGCC, CADD 15.40
- G66G (p.Gly66Gly), gnomAD 22-41926270-C-G, CADD 3.09
- G66E (p.Gly66Glu), gnomAD 22-41926271-C-T, REVEL 0.03, MetaLR 0.05
- A67S (p.Ala67Ser), rs1050585658, ClinGen CA411763294, ClinVar RCV002302153, REVEL 0.01, CADD 0.17, Uncertain significance, Immunodeficiency, common variable, 4
- A67T (p.Ala67Thr), rs1050585658, ClinGen CA324633614, ClinVar RCV001036651, ClinVar RCV004877694, REVEL 0.02, CADD 0.30, Uncertain significance, not specified; Immunodeficiency, common variable, 4
- A67V (p.Ala67Val), TOPMed rs1392495883, gnomAD rs1392495883, REVEL 0.03, CADD 6.94
- A67A (p.Ala67Ala), rs1047109296, gnomAD 22-41926267-G-C, CADD 5.64
- A67P (p.Ala67Pro), rs1469524347, gnomAD 22-41926268-GC-G, CADD 9.10
- A67G (p.Ala67Gly), gnomAD 22-41926268-G-C, REVEL 0.03, MetaLR 0.04
- G68C (p.Gly68Cys), ExAC rs756436527, TOPMed rs756436527, gnomAD rs756436527, Uncertain significance
- G68R (p.Gly68Arg), ExAC rs756436527, TOPMed rs756436527, gnomAD rs756436527, REVEL 0.08, CADD 9.88, Uncertain significance
- G68S (p.Gly68Ser), rs756436527, ClinGen CA411763290, ClinVar RCV003612215, ExAC rs756436527, REVEL 0.02, CADD 1.22, Uncertain significance, Immunodeficiency, common variable, 4
- G68G (p.Gly68Gly), rs1330131673, gnomAD 22-41926264-G-A, CADD 7.32
- G68D (p.Gly68Asp), gnomAD 22-41926265-C-T, REVEL 0.03, MetaLR 0.03
- G68V (p.Gly68Val), gnomAD 22-41926265-C-A, REVEL 0.03, MetaLR 0.03
- G68A (p.Gly68Ala), rs932166932, gnomAD 22-41926266-CG-C, CADD 15.10
- E69* (p.Glu69Ter), gnomAD rs1197094670, CADD 34.00
- E69D (p.Glu69Asp), gnomAD 22-41926261-C-G, REVEL 0.02, MetaLR 0.04
- E69E (p.Glu69Glu), rs752818355, gnomAD 22-41926261-C-T, CADD 6.35
- E69K (p.Glu69Lys), gnomAD 22-41926263-C-T, REVEL 0.05, MetaLR 0.04
- A70E (p.Ala70Glu), gnomAD rs1234917601, REVEL 0.03, CADD 4.31, Uncertain significance
- A70T (p.Ala70Thr), gnomAD rs1247166576, REVEL 0.06, CADD 9.61
Public TNFRSF13C analysis runs
- TNFRSF13C analysis run — TNFRSF13C (533 variants) — completed 2026-08-22